CYTORA is a clinical stage stem cell company developing a new class of medicines based on a novel and transformative patented platform stem cell technology derived from unique human Oral Mucosa Stem Cells (hOMSC)
CYTORA has developed a revolutionary patent protected technology platform to produce “off the shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade including chronic wounds such as incurable diabetic foot ulcers (IDFU) and degenerative diseases such as Parkinson's Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease.
Our pioneering and deeply scientific team are leading the way in stem cell therapy have years of research, patents and industry experience in the fields of biotechnology and stem cell therapy.
Our vision is to improve and save the lives of millions of patients worldwide through our unique patented stem cell platform technology, making it accessible and affordable.
Company Details
- Employees
- 16
- Founded
- -
- Address
- Hayozma Street, Colab Square,israel
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- Stem cell therapy, human Oral Mucosa Stem Cells ( hOMSC), Biotechnology, Neurodegenerative disease, Wound healing.
- HQ
- Yokneam
Cytora Stem Questions
Cytora Stem's LinkedIn profile is https://il.linkedin.com/company/cytora-stem
Cytora Stem has
16 employees.
View email and phone details for 16
employees at Cytora Stem.
Cytora Stem's industry is
Pharmaceutical Manufacturing
Cytora Stem's top competitors are
Pluri,
Cytora,
Nanosono,
Gsap,
Bonus Biogroup,
Anserbio,
Biotav Shield Ltd.,
Teracyte Analytics,
Memed,
Novocure.
Cytora Stem's categories are Pharmaceutical Manufacturing
Cytora Stem's founding year is 2018
